131 related articles for article (PubMed ID: 18575729)
1. Geographic variations of human papilloma virus infection and their possible impact on the effectiveness of the vaccination programme.
Mammas IN; Vageli D; Spandidos DA
Oncol Rep; 2008 Jul; 20(1):141-5. PubMed ID: 18575729
[TBL] [Abstract][Full Text] [Related]
2. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination.
Chen CJ; Viscidi RP; Chuang CH; Huang YC; Chiu CH; Lin TY
J Clin Virol; 2007 Feb; 38(2):126-30. PubMed ID: 17210269
[TBL] [Abstract][Full Text] [Related]
4. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus infection: epidemiology and pathophysiology.
Steben M; Duarte-Franco E
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S2-5. PubMed ID: 17938014
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination.
Bhatla N; Lal N; Bao YP; Ng T; Qiao YL
Vaccine; 2008 Jun; 26(23):2811-7. PubMed ID: 18450340
[TBL] [Abstract][Full Text] [Related]
7. The distribution of Human Papilloma Virus infection in women with cervical histological abnormalities from an area with high incidence of cervical cancer.
Fanta BE
Ethiop Med J; 2005 Jul; 43(3):151-8. PubMed ID: 16370546
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study.
Dondog B; Clifford GM; Vaccarella S; Waterboer T; Unurjargal D; Avirmed D; Enkhtuya S; Kommoss F; Wentzensen N; Snijders PJ; Meijer CJ; Franceschi S; Pawlita M
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1731-8. PubMed ID: 18628425
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of human papillomavirus types 6, 11, 16, 18, 31, and 33 in a cohort of Greek women.
Panotopoulou E; Tserkezoglou A; Kouvousi M; Tsiaousi I; Chatzieleftheriou G; Daskalopoulou D; Magiakos G
J Med Virol; 2007 Dec; 79(12):1898-905. PubMed ID: 17935171
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of HPV types in a cohort of Greeks with clinical indication of infection.
Yapijakis C; Adamopoulou M; Antonopoulos G; Koufaliotis N; Vairaktaris E
Anticancer Res; 2008; 28(4B):2233-7. PubMed ID: 18751400
[TBL] [Abstract][Full Text] [Related]
13. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
15. [Knowledge of HPV-related genital lesions and of anti-HPV vaccination in a sample of women of north-eastern Italy].
Sopracordevole F; Cigolot F; Lucia E; Marchesoni D
Minerva Ginecol; 2009 Apr; 61(2):81-7. PubMed ID: 19255555
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus and mutated H-ras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: a retrospective follow-up.
Landro ME; Dalbert D; Picconi MA; Cúneo N; González J; Vornetti S; Bazán G; Mural J; Basiletti J; Teyssié AR; Alonio LV
J Med Virol; 2008 Apr; 80(4):694-701. PubMed ID: 18297710
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.
Agarossi A; Ferrazzi E; Parazzini F; Perno CF; Ghisoni L
J Med Virol; 2009 Mar; 81(3):529-35. PubMed ID: 19152401
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.
Domingo EJ; Noviani R; Noor MR; Ngelangel CA; Limpaphayom KK; Thuan TV; Louie KS; Quinn MA
Vaccine; 2008 Aug; 26 Suppl 12():M71-9. PubMed ID: 18945416
[TBL] [Abstract][Full Text] [Related]
20. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
